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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) vGPCR is a constitutively active G pro-
tein-coupled receptor that subverts proliferative and inflammatory signaling pathways to
induce cell transformation in Kaposi’s sarcoma. Cyclooxygenase-2 (COX-2) is an inflamma-
tory mediator that plays a key regulatory role in the activation of tumor angiogenesis. Using
two different transformed mouse models and tumorigenic full KSHV genome-bearing cells,
including KSHV-Bac16 based mutant system with a vGPCR deletion, we demostrate that
vGPCR upregulates COX-2 expression and activity, signaling through selective MAPK cas-
cades. We show that vGPCR expression triggers signaling pathways that upregulate COX-
2 levels due to a dual effect upon both its gene promoter region and, in mature mRNA, the
3’UTR region that control mRNA stability. Both events are mediated by signaling through
ERK1/2 MAPK pathway. Inhibition of COX-2 in vGPCR-transformed cells impairs vGPCR-
driven angiogenesis and treatment with the COX-2-selective inhibitory drug Celecoxib pro-
duces a significant decrease in tumor growth, pointing to COX-2 activity as critical for
vGPCR oncogenicity in vivo and indicating that COX-2-mediated angiogenesis could play a
role in KS tumorigenesis. These results, along with the overexpression of COX-2 in KS
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Author summary
Kaposi sarcoma (KS) is the most frequent AIDS-related cancer (AIDS-KS). The tumors
originate in cells infected with a cancer-causing virus (KSHV). A gene encoded by the
virus expresses a protein with oncogenic potential in the infected cells (vGPCR), which
has the ability to promote cell transformation and angiogenesis driving KS tumorigenesis.
Therefore, the identification of oncogenic intracellular signalling mechanisms triggered
by vGPCR could be of therapeutic interest. Cyclooxygenase-2 (COX-2) is an inflamma-
tory molecule involved in tumor angiogenesis that can be targeted by several FDA-
approved non-steroidal anti-inflammatory drugs and specific inhibitors. Here, we demon-
strate that vGPCR upregulates COX-2 activity and expression through upregulation of
transcription and mRNA stability via an ERK1/2 dependent pathway. We also show that
COX-2 activity is critical for vGPCR angiogenesis and oncogenesis using KSHV infection
and mouse models. Consistent with a role in KS pathogenesis, we found that vGPCR
upregulates COX-2 activity in endothelial cells, that it is essential for VEGF upregulation
via vGPCR, and that it is expressed in KSHV infected cells of AIDS-KS lesions. These facts
point to COX-2 as one of the molecular components of the vGPCR angiogenic switch in
Kaposi Sarcoma and a potential target for chemoprevention and therapy.
Introduction
Kaposi’s sarcoma (KS) is among the most common type of cancers associated with the
Acquired Immunodeficiency Syndrome (AIDS, AIDS-KS) [1–4]. KS arises as multifocal
lesions in the skin, lungs and gastrointestinal tract characterized by intense angiogenesis, spin-
dle cell proliferation and erythrocyte extravasation [1–5]. Early KS lesions are treated with
local and non-toxic therapies; however, advanced KS is treated with systemic chemotherapy,
which is difficult to tolerate for AIDS patients [3,6,7]. Thus, the development of rational thera-
pies based on KS pathogenesis is critical to fill this gap [3,6,8,9]. KS is caused by the KS herpes-
virus (KSHV) or Human herpesvirus-8 (HHV-8), an oncogenic γ-2-herpesvirus, which carries
several viral oncogenes responsible for the KS angiogenic phenotype [4,10–13]. KSHV encodes
several open reading frames for proteins with the potential to regulate host-cell oncogenic sig-
naling mechanisms [14]. ORF74 expression renders a constitutively active G-protein coupled
receptor (vGPCR) homologous to angiogenic-chemokine receptors [15–17]. vGPCR has been
identified as a major KSHV angiogenesis activating oncogene [18–20] that subverts host-cell
proliferative and inflammatory signaling cascades leading to tumorigenicity and VEGF-medi-
ated angiogenesis [18,21,22], and it has been shown to produce KS-like angioproliferative
lesions in mice [20,23–25]. vGPCR immortalizes human endothelial cells by autocrine activa-
tion of the VEGF receptor [17] and upregulates PDGF expression via a Rac1-NOX-ROS oxida-
tive stress axis [26]. All these facts identify vGPCR, and the molecular components of the pro-
angiogenic signaling pathways that triggers, as targets for preventing and treating KS.
Cyclooxygenase-2 (COX-2) is an inflammatory mediator that plays a key regulatory role in
the activation of tumor angiogenesis [27,28], and it is constitutively expressed in some human
cancers [29,30], including KS lesions (skin tissue and lymph node) [31]. Moreover,
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Cyclooxygenase-2 (COX-2), is one of the host genes that is highly induced upon KSHV de
novo infection of human microvascular endothelial cells (HMVEC-d) and human foreskin
fibroblast (HFF) cells [31–35], and COX-2 silencing or chemical inhibition significantly
reduces the proliferation and invasiveness of KSHV-infected endothelial cells [31, 32,34–38].
COX proteins catalyze the metabolism of arachidonic acid to produce prostaglandins as PGE-
2 [29]. Accordingly, high levels of PGE2 secretion have been observed during KSHV primary
infection [32,33] and PGE2 receptors have also been shown to be expressed in KS and PEL tis-
sues [39]. Furthermore, COX-2 has been reported as a possible target of the drug nimesulide
in PEL treatment [37].
Molecular mechanisms that regulate COX-2 promoter activation and mRNA stability by
KSHV in relevant oncogenesis models are limited [31,35,40–43]. It has been shown that COX-
2 gene expression can be down-regulated by EP2 and EP4 antagonist through its promoter or
mRNA half-time regulation [39]. Moreover, in vitro angiogenic models and in vivo tumori-
genic models are needed to further validate COX-2 and PGE2 inhibitors as novel KS therapeu-
tic targets. Using two different transformed mouse-cell models and tumorigenic full KSHV
genome-bearing cells, including KSHV-Bac16 based mutant system, we demostrate that
vGPCR upregulates COX-2 expression and activity, signaling through selective MAPK cas-
cades. We show that in addition to inducing COX-2 gene promoter activation, vGPCR can
induce the stabilization of COX-2 mRNAs through ERK1/2 signaling pathways. We found
that COX-2 plays a key role in vGPCR angiogenesis in murine skin and tumors indicating that
COX-2 could be a link between vGPCR signaling and angiogenesis regulation. Moreover,
using KS biopsies we show that COX-2 is overexpressed in KSHV-infected cells of KS lesions,
defining COX-2 as a potential target for preventing and treating KSHV-oncogenesis.
Results
vGPCR regulates COX-2 activity and expression
We and others have found that vGPCR induces angiogenesis and tumorigenesis in NIH3T3
cells and SV-40 Large T antigen immortalized mouse endothelial cells (SVECs) [18,20]. COX-
2 is an important inflammatory mediator of tumor angiogenesis and an attractive chemopre-
vention target that could be inhibited by many Nonsteroidal Anti-Inflammatory Drugs
(NSAIDS). We analyzed the expression of COX-2 in cells that express KSHV-encoded
vGPCR. We observed a strong upregulation of COX-2 mRNA in vGPCR expressing cells
respect to control cells (Fig 1A). To study whether vGPCR can upregulate COX-2 activity, we
compared the ability of vGPCR-expressing cells versus control cells to produce prostaglandin
E2 (PGE2), using PGE2 enzyme immunoassay. We found that PGE2 synthesis was four times
higher in vGPCR-expressing cells than in NIH3T3 controls (Fig 1B). To determine whether
vGPCR signaling was directly involved in increasing COX-2 activity, we used the vGPCR full
agonist Gro-α and found that vGPCR stimulation by Gro-α enhanced PGE2 production in
vGPCR-expressing cells. NS398, a specific COX-2 inhibitor, blocked vGPCR induced PGE2
synthesis, suggesting that vGPCR-induced PGE2 production is dependent on the expression
of an active COX-2. Taken together, these results indicate that vGPCR signaling stimulates
COX-2 activity and consequent PGE2 production in NIH3T3 cells.
We next studied the ability of vGPCR expression to upregulate COX-2 in SVECs, a mouse
endothelial cell system that was previously used to characterize mechanisms of vGPCR
induced angiogenesis and tumorigenesis in a relevant target cell type [20]. We analyzed SVEC
cell lysates both by RT-qPCR and immunoblot using specific primers and a murine COX-2
monoclonal antibody. We found an increase in mRNA and protein levels of COX-2 in
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Fig 1. vGPCR oncogene expression increases COX-2 mRNA and protein expression levels as well as COX-2 activity. A) Fold-
changes of COX-2 mRNA expression in transformed NIH3T3 (NIHT3T3-vGPCR) cells that stably express the vGPCR oncogene and
control cells were assessed by RT-qPCR in triplicate and are presented as means ± SD. (�P<0.05). B) NIH3T3 cells were transfected
with vGPCR expression vectors and were incubated ON in serum-free media. The vGPCR full agonist Gro-α (25nM), the COX-2
inhibitor NS398 (10uM), the ERK1/2 MAPK inhibitor PD98059 (20uM), or the p38 inhibitor SB220025 (10uM) were added to the cells
as indicated. COX-2 activity was assessed measuring PGE2 production in the supernatants by an ELISA. Bars indicate mean PGE2
production of duplicate determinations ± SD. (�) Indicates significant differences between NIH3T3 control cells and the
NIH3T3-vGPCR group of samples (P<0.05). (#) Indicates significant differences between sets of NIH3T3-vGPCR cells (P<0.05). C)
PLOS PATHOGENS KSHV vGPCR activates COX-2 in Kaposi’s sarcoma
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009006 October 15, 2020 4 / 25
vGPCR-transformed cells respect to control cells (Fig 1C and 1D), which correlates with an
increase in COX-2 activity (Fig 1E) as already shown for NIH3T3 cells.
Since vGPCR constitutive signaling activates members of MAP kinase family cascade
[18,21,44], we analyzed whether vGPCR activates COX-2 via p38 or ERK1/2. We found that
vGPCR-expressing cells treated with the ERK1/2 inhibitor PD98059 showed a marked
decrease in the levels of COX-2 activity. In contrast, while the p38 inhibitor SB220025 did not
have any significant effect in NIH3T3-vGPCR cells (Fig 1B) it rendered upregulation of PGE2
secretion in SVEC-vGPCR cells (Fig 1E). Both pieces of information support that p38 MAPK
is not involved in the signaling pathway that leads to increased COX-2 activation. MAPK acti-
vation was confirmed by the determination of ERK1/2 phospho-protein levels. We found that
ERK1/2 was potently and significantly activated by phosphorylation only in vGPCR-express-
ing cells (Fig 1F). The vGPCR-triggered activation of ERK1/2 was confirmed by using the
MAPK pharmacological inhibitor to MAPKK MEK1, PD98059 which impairs ERK1/2 MAPK
signaling and significantly reduced and almost completely abolished ERK1/2 activation in
vGPCR expressing cells. On the other hand, NS398 (a well-known COX-2 inhibitor) and
SB203580 (a well-known p38 MAPK inhibitor) showed no effect (Fig 1F). Gro-α treatment
did not increase ERK1/2 phosphorylation levels further to what vGPCR already increases. Pre-
vious results with vGPCR expressing HUVECs [17] showed that in cells where basal levels of
ERK1/2 due to constitutive signaling were undetectable, Gro-α superactivation led to ERK1/2
phosphorylation. Since in the case of SVECs vGPCR expression and constitutive signaling
already stimulates ERK1/2 (Fig 1F lanes 1 and 2), it is likely that the apparent lack of Gro-α
stimulation of ERK1/2 in SVEC cells is due to the maximal stimulation and saturation of the
ERK1/2 signaling pathway already achieved by the over expression of vGPCR in this system.
Taken together our data shows that vGPCR signaling upregulates COX-2 expression and activ-
ity via ERK1/2.
vGPCR upregulates COX-2 transcription via ERK1/2
To evaluate if the vGPCR upregulation of COX-2 was due to transcriptional activation, we
used a luciferase reporter under the control of an active portion of the COX-2 promoter [45].
Shelby et al. have provided evidence that KSHV vGPCR induces COX-2 transcription in pri-
mary vascular endothelial cells [41]. We found that both vGPCR transient and stable expres-
sion in SVECs upregulates COX-2 promoter activity (Fig 2A and 2B). Since ERK1/2 activation
is known to regulate gene transcription, we analyzed by qRT-PCR whether vGPCR up-regula-
tion of COX-2 mRNA expression was MAPK dependent. Pharmacological inhibition of the
ERK1/2 signaling pathway was achieved by adding the specific inhibitor of the MAPKK MEK1
PD98059 (Fig 2C). Alternatively, as the use of pharmacological inhibitors may have potential
Fold-changes of COX-2 mRNA expression in transformed SVEC (SVEC-vGPCR) cells that stably express the vGPCR oncogene and
control cells were assessed by RT-qPCR in triplicate and are presented as means ± SD. (�P<0.05). D) COX-2 protein expression levels
were determined by immunoblotting in SVEC cells that stably express the vGPCR oncogene. GAPDH was used as a loading control.
COX-2 protein levels were measured in triplicate and are presented as means ± SD. (�P<0.05). E) SVEC cells were transfected with
vGPCR expression vectors and were incubated ON in serum-free medium. The vGPCR full agonist Gro-α (25nM), the COX-2 inhibitor
NS398 (10uM), the ERK1/2 MAPK inhibitor PD98059 (20uM), or the p38 inhibitor SB203580 (10uM) were added to the cells as
indicated. COX-2 activity was assessed measuring PGE2 production in the cell supernatants by an ELISA. Bars indicate mean PGE2
production of duplicate determinations ± SD. (�) Indicates significant differences between samples from SVEC control cells and the
SVEC-vGPCR group of samples (P<0.05). (#) Indicates significant differences between sets of SVEC-vGPCR cells (P<0.05). F) Total
and phospho-ERK1/2 levels were determined by immunoblotting in SVEC cells transfected with vGPCR. The ERK1/2 MAPK inhibitor
PD98059 (20uM), the p38 inhibitor SB203580 (10uM), the COX-2 inhibitor NS398 (10uM), or the vGPCR full agonist Gro-α (25nM)
were added to the cells as indicated. Actin was used as loading control. pERK1/2 levels related to Total ERK1/2 levels were measured in
triplicate and are presented as means ± SD. (�) Indicates significant differences between samples from SVEC control cells and the SVEC-
vGPCR group of samples (P<0.05). (#) Indicates significant differences between sets of SVEC-vGPCR cells (P<0.05).
https://doi.org/10.1371/journal.ppat.1009006.g001
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Fig 2. vGPCR signaling regulates COX-2 promoter activity and induces mRNA stability via ERK1/2. A) SVEC cells were transfected
at increasing concentrations with a vGPCR expression vector and a luciferase reporter plasmid under the control of the COX-2
promoter. Luciferase activity expressed as fold induction relative to control cells that do not express vGPCR. Luciferase activity was
measured in triplicate and is presented as means ± SD. (�P<0.05). B) Stably transfected SVEC-vGPCR cells and control cells were
transfected with a luciferase reporter plasmid under the control of the COX-2 promoter. Luciferase activity was measured in triplicate
and is presented as means ± SD. (�P<0.05) and expressed as fold induction relative to control cells. C) A reporter that expresses
Luciferase under the control of a COX- 2 gene promoter region was co-transfected with a vGPCR expression vector and plasmids
expressing constitutively active and dominant negative MAP kinase kinases (MEKEE and MEKAA respectively) or treated with the
MEK/ERK1-2 inhibitor PD98059. Luciferase activity was tested and presented as fold induction relative to SVEC control cells. (�)
Indicates significant differences relative to SVEC control untreated cells (P<0.05). (#) Indicates significant differences relative to SVEC-
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off-target effects, we used a different method to validate these findings. Cells were transfected
with constitutively active or dominant negative (kinase-dead) MEK1 mutants (MEKEE and
MEKAA, respectively). While activation of the MEK1-ERK1/2 axis increased COX-2 promoter
activity per se, both the pharmacological inhibitor and the dominant negative MEK1 mutant
showed a reduction of vGPCR induced luciferase activity. Overall, results in Fig 2C support
the involvement of the MEK1-ERK1/2 axis in signaling from vGPCR to the COX-2 promoter.
vGPCR signaling induces COX-2 mRNA stability
The stability of the COX-2 messenger RNA (mRNA) transcript has been shown to be mediated
by p38/MK2 dependent signaling acting on the ARE sequences in the 30 UTR region of the
COX-2 mRNA [46]. Working with a plasmid that expresses luciferase fused to the 3’-UTR of
COX-2 mRNA, we showed that vGPCR expressing cells induce stabilization of mRNAs con-
taining the COX-2 3’UTR (Fig 2D). This mRNA stabilization is ERK1/2 MAPK dependent as
it was abolished in the vGPCR expressing cells upon treatment with the MEK inhibitor
PD98059 (Fig 2E).
Using full KSHV genome bearing cells to analyze COX-2 expression
regulation by vGPCR
KSHV harbors several open reading frames that encode proteins with the potential to regulate
host-cell oncogenic signaling mechanisms. To study the regulation of COX-2 by vGPCR in the
context of cells bearing the full KSHV genome we used tetracycline-inducible vGPCR (TET-
vGPCR) overexpression in a mouse bone-marrow endothelial-lineage cells (mEC) transfected
with the KSHVBac36 (a bacterial artificial chromosome that contained the whole KSHV
genome), mECK36 cells [26]. Similar to the observation in vGPCR transformed cells, in the
presence of KSHV, vGPCR overexpression leads to a potent COX-2 mRNA and protein upre-
gulation as detected by qRT-PCR (Fig 3A), Western blots (Fig 3B) and IFA (Fig 3C).
To determine the specific contribution of vGPCR signaling to the expression of COX-2 in
the context of KSHV, we used the Bac16 based mutant system. We used the procedure
described in Ashlock et al. to “swap” Bac36 for the Bac16-delta vGPCR mutant or its revertant
in mECK36 cells that have lost the Bac36 episome by lack of antibiotic selection (KSHV-nega-
tive cells, mEC) (See Materials and methods) [47], to generate the cell lines mECK16-ΔvGPCR
and mECK16-revertant, respectively. Fig 3D and 3H show a sharp drop in COX-2 mRNA and
protein expression when mECK36 cells lose the KSHV episome indicating that, as shown in
other infection systems, KSHV induces COX-2 upregulation. We found a similar drop in
COX-2 expression between Bac16-revertant bearing cells and the vGPCR deletion mutant (Fig
3E and 3H). Since LANA and vFLIP has been shown to activate COX-2 [35] and in order to
rule out effects in COX-2 regulation due to downregulation of these viral genes caused by
vGPCR deletion in the Bac16 mutant, we assessed their expression levels by qRT-PCR. Inter-
estingly, vGPCR deletion mutant showed more expression of LANA and similar expression
levels of vFLIP than mECK16 revertant cells (S1 Fig). Taken together these results reinforce
the idea that the effects on COX-2 downregulation in the Bac16 mutant are due to vGPCR
vGPCR untreated cells (P<0.05). D) mRNA stability assays were performed using a reporter plasmid containing the COX-2 3’UTR
region cloned downstream of the luciferase ORF from SVEC or SVEC-vGPCR cells. Actinomycin D (5 μg/ml) was added (t = 0) to arrest
transcription, and mRNA levels of Luciferase mRNA were analyzed by qRT-PCR following a time course (4 hours). Luciferase mRNA
was measured in triplicate and is presented as means ± SD. (�P<0.05). E) mRNA stability assays in SVEC-vGPCR cells transfected with
the same reporter plasmid as in D) in the presence or absence of the MEK/ERK1-2 inhibitor PD98059 (20 uM). Actinomycin D (5 μg/
ml) was added (t = 0) to arrest transcription, and mRNA levels of Luciferase mRNA were analyzed by qRT-PCR following a time course
(4 hours). Luciferase mRNA was measured in triplicate and is presented as means ± SD. (�P<0.05).
https://doi.org/10.1371/journal.ppat.1009006.g002
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Fig 3. Use of full KSHV genome bearing cells to analyze COX-2 expression regulation by vGPCR. A) Fold-changes of COX-2
mRNA expression determined by RT-qPCR in Tetracycline-inducible vGPCR (TET-vGPCR) and control mECK36 cells stimulated
with doxycycline for 24 hours. COX-2 mRNA was measured in triplicate and is presented as means ± SD. (�P<0.05). B) COX-2
protein expression levels were determined by immunoblotting in Tetracycline-inducible vGPCR (TET-vGPCR) and control
mECK36 cells stimulated with doxycycline for 24 hours. GAPDH was used as a loading control. C) IFA for COX-2 (red) in
Tetracycline-inducible vGPCR (TET-vGPCR) and control mECK36 cells stimulated with doxycycline for 24 hours. Cell nuclei were
counterstained with DAPI (blue). D) Fold-changes of COX-2 mRNA expression determined by RT-qPCR in mECK36 and mEC
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deletion. Importantly, in contrast to mEC and Bac16Δ-vGPCR that showed no vGPCR expres-
sion, mECK36 cells and Bac16-revertant showed vGPCR expression as detected by qRT-PCR
(Fig 3F and 3G). This data strongly suggests that most of the COX-2 upregulation in mECK36
and KSHVBac16 bearing cells is due to the presence of the vGPCR oncogene. Inhibition of
MAPK signaling in this cellular setting by the addition of the MEK inhibitor PD98059 is con-
sistent with data already shown in this study (Fig 2C), indicating that COX-2 activation by
vGPCR is dependent on ERK1/2 signaling, as we found a downregulation of COX-2 expres-
sion in Bac16-revertant bearing cells treated with the MEK inhibitor (Fig 4A). Finally, we
tested COX-2 promoter activity and mRNA stability in the KSHVBac16 cells expressing or not
vGPCR, and we found that in the context of KSHV, vGPCR is a major contributor to COX-2
expression by triggering signaling that induces COX-2 promoter activity and mRNA stability
via ERK1/2 MAPK (Fig 4B and 4C). Working with a plasmid that expresses luciferase fused to
the 3’-UTR of COX-2 mRNA, we showed that vGPCR expressing cells induce stabilization of
mRNAs containing the COX-2 3’UTR (Fig 4D). This vGPCR-driven mRNA stabilization is
ERK1/2 MAPK dependent as it was abolished in the vGPCR expressing cells and not in
vGPCR mutant cells upon treatment with the MEK inhibitor PD98059 (Fig 4D).
COX-2 regulates vGPCR angiogenicity
COX-2 expression has been shown to regulate the angiogenicity of tumor cells [27]. Since
vGPCR is an angiogenesis activator [18] and vGPCR activates COX-2 in NIH3T3 and SVEC
cells (Fig 1), we sought to determine whether COX-2 activity modulates the angiogenesis
induced by vGPCR in transformed cells using an intradermal angiogenesis assay [48]. We
inoculated one group of nude mice with vGPCR-transformed NIH3T3 cells and another with
vGPCR-transformed NIH3T3 cells pre-treated with NS398, a COX-2 inhibitor. Trypan blue
exclusion was used to ensure that the same number of viable cells were injected in all the ani-
mals and to mark the site of injection. In parallel, cells treated or not with NS398 were main-
tained in culture for the duration of the animal experiment to rule out effects due to decreased
cell viability. Mice inoculated with vGPCR-transformed NIH3T3 cells induced neo-vascula-
ture intricacy and more vessel density than NIH3T3 cells inoculated mice (Fig 5A) which only
presented straight mature vessels at the inoculation in their skin. Like these NIH3T3 controls,
NS398 pretreated vGPCR-transformed cells did not induce microvessel proliferation at the site
of inoculation (Fig 5A). Morphometric quantification and statistical analysis of the angiogenic
response showed a significant increase of more than two-fold in the density of vessels deter-
mined on the skin of the group of mice injected with vGPCR-transformed cells (Fig 5B). On
the other hand, vessel density in the group inoculated with vGPCR-transformed cells pre-
treated with NS398 did not show significant differences compared to group injected with
NIH3T3 control cells (Fig 5B). This indicates that treatment of the cells with NS398 before
cells (originated from the former and generated by selection of those that have lost the KSHVBAC36). COX-2 mRNA was measured
in triplicate and is presented as means ± SD. (�P<0.05). E) Fold-changes of COX-2 mRNA expression determined by RT-qPCR in
mECK16 derived Δ-vGPCR or revertant virus (see Materials and methods). COX-2 mRNA was measured in triplicate and is
presented as means ± SD. (�P<0.05). F) vGPCR mRNA expression determined by RT-qPCR in mECK36 and mEC cells (KSHV-
negative cells originated from the former and generated by selection of those that have lost the KSHVBAC36). The lowest CT value
obtained in KSHV-negative mEC cell samples was assigned as the limit of detection for vGCPR expression. vGPCR mRNA was
measured in triplicate and is presented as means ± SD. (�P<0.05). G) vGPCR mRNA expression determined by RT-qPCR in
mECK16 derived Δ-vGPCR or revertant virus (see Materials and methods). The lowest CT value obtained in mECK16 Δ-vGPCR cell
samples was assigned as the limit of detection for vGCPR expression. vGPCR mRNA was measured in triplicate and is presented as
means ± SD. (�P<0.05). H) COX-2 protein expression levels were determined by immunoblotting in mECK36, mEC and mECK16
derived Δ-vGPCR or revertant virus (see Materials and methods). COX-2 protein levels were measured in triplicate and are
presented as means ± SD. (�P<0.05).
https://doi.org/10.1371/journal.ppat.1009006.g003
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inoculation abolished the angiogenic response induced by vGPCR expression, suggesting that
a COX-2 dependent pathway has a major contribution to in vivo angiogenesis mediated by
vGPCR signaling in NIH3T3 cells.
COX-2 mediates vGPCR tumorigenicity
To analyze the contribution of COX-2 mediated angiogenesis to vGPCR-induced tumorigene-
sis [18], we investigated the effect of treatment with the COX-2 selective inhibitory drug Cele-
coxib on the growth of vGPCR-transformed NIH3T3 tumors [49]. To confirm that NIH3T3-
vGPCR induced-tumors expressed COX-2, we performed COX-2 inmunostaining and found
that these tumors showed a high COX-2 expression (S2 Fig) indicating that COX-2 is expressed
Fig 4. vGPCR regulates COX-2 promoter activity and mRNA stability via ERK1/2 in full KSHV genome bearing cells. A) Fold-changes in mRNA
expression determined by RT-qPCR in mECK16 derived cells (Δ-vGPCR or revertant virus) after treatment with ERK1/2 MAPK inhibitor PD98059
(20uM). COX-2 mRNA was measured in triplicate and is presented as means ± SD. (�P<0.05). B) mECK16 derived Δ-vGPCR and revertant cells were
transfected with a luciferase reporter plasmid under the control of the COX-2 promoter (as in Fig 2A). Luciferase activity is expressed as fold induction
relative to control cells. Cells were co-transfected with plasmids expressing constitutively active and dominant negative MAP kinase kinases (MEKEE
and MEKAA respectively) or treated with the MEK/ERK1-2 inhibitor PD98059. (�) Indicates significant differences from mECK16 Δ-vGPCR untreated
cells (P<0.05). (#) Indicates significant differences between mECK16 revertant untreated cells (P<0.05). C) mRNA stability assay in mECK16 derived
(Δ-vGPCR and revertant) cells. Actinomycin D (5 μg/ml) was added (t = 0) to arrest transcription, and mRNA levels of COX-2 were analyzed by
qRT-PCR following a time course (4 hours). COX-2 mRNA was measured in triplicate and is presented as means ± SD. (�P<0.05). D) mRNA stability
assay in mECK16 derived (Δ-vGPCR and revertant) cells transfected with a reporter plasmid containing the COX-2 3’UTR region cloned downstream
of the luciferase ORF in the presence or absence of the MEK/ERK1-2 inhibitor PD98059 (20 uM). Actinomycin D (5 μg/ml) was added (t = 0) to arrest
transcription, and mRNA levels of Luciferase were analyzed by qRT-PCR following a time course (4 hours). Luciferase mRNA was measured in
triplicate and is presented as means ± SD. (�P<0.05).
https://doi.org/10.1371/journal.ppat.1009006.g004
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in vGPCR induced tumors. We subcutaneously (S.C.) inoculated nude mice with vGPCR-trans-
formed NIH3T3 cells and treated one group with Celecoxib intraperitoneally (I.P.) three times
a week and another group with the vehicle (DMSO) as control. We found that Celecoxib pro-
duced consistent retardation in the occurrence of tumors and a significant decrease in tumor
growth (Fig 6A and 6B). Histological analysis revealed that the untreated group presented large
areas of hemorrhage and necrosis, attributable to the large size of the tumor and outgrowth of
the vascular supply (Fig 6C, left panels black arrows). The group treated with Celecoxib did not
show necrosis in the tumor and showed only marginal hemorrhage (Fig 6C, right panels).
These results indicate that COX-2 contributes to the growth of tumors induced by vGPCR and
that treatment of mice with Celecoxib was effective in reducing tumor growth.
COX-2 modulates tumor angiogenesis by regulating VEGF production in
tumor cells
To evaluate whether the anti-tumor effects caused by COX-2 inhibition were related to tumor
angiogenesis inhibition, we quantified tumor vascularization by immunostaining. We used
CD31/PECAM, a pan-endothelial marker, to stain tumor vessels as well as α-Smooth Muscle
Actin (α-SMA) to stain pericyte-containing mature vessels [50]. Celecoxib treatment led to a
dramatic reduction in both total (CD31+) and α-SMA+ vessels in NIH3T3-vGPCR tumors
(Fig 7A, left panel), indicating that COX-2 inhibition greatly compromised vGPCR tumor
angiogenicity. Statistical analysis of the data from immunostaining quantification (Fig 7A,
right panel), indicate a significant decrease in CD31+ total vessels (163 +/-29 vs 73 +/-21) and
SMA+ mature vessels (185 +/-63 vs 64 +/-40) in the tumors from animals treated with Cele-
coxib. These results show that Celecoxib treatment of mice reduced the total number of vessels
in tumors and inhibited their maturation, indicating that a COX-2 dependent pathway con-
tributes to vGPCR tumor angiogenicity.
Since our results in vivo indicated that COX-2 affects vGPCR angiogenicity (Fig 5) and
tumorigenicity (Fig 6) and VEGF secretion is essential for tumor angiogenesis, we tested
Fig 5. COX-2 regulates vGPCR angiogenicity. A) Cells expressing vGPCR and corresponding controls were treated or not with NS398
(10 mM) and inoculated I.D. into both flanks of nude mice (n = 5). Mice were sacrificed after 5 days and the area of inoculation was
photographed under a dissection microscope. B) Neovessel formation determined by morphometric analysis. The bar graphs show the
mean microvessel density (vessels/mm2) for NS398 pre-treated (grey bars) or untreated (black bars) cells +/-SD. Total n (both flanks) =
10. (�) Indicates significant differences between groups injected with vGPCR-transformed cells and NIH3T3 control cells (P<0.05). (#)
Indicates significant differences between groups injected with NS398-treated and non-treated vGPCR-transformed cells (P<0.01).
https://doi.org/10.1371/journal.ppat.1009006.g005
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modulation of VEGF expression by COX-2 inhibitors in the tumors. We compared the levels
of VEGF extracted from tumors of Celecoxib treated and untreated animals. Tumors from ani-
mals treated with Celecoxib produced significantly lower levels of VEGF than tumors from
untreated animals (Fig 7B). Since COX-2 was shown to be able to regulate VEGF expression in
transformed cells [27], we tested in cultured NIH3T3-vGPCR cells whether inhibition of
COX-2 could affect VEGF secretion. We found that COX-2 inhibitors caused a dramatic
reduction in VEGF secretion of NIH3T3-vGPCR without affecting cell growth (Fig 7C).
Taken together our results suggest that COX-2 inhibition blocks tumor angiogenesis at least
partly by inhibiting VEGF secretion by vGPCR expressing cells.
COX-2 is overexpressed in KSHV-infected spindle cells in Kaposi’s
sarcoma
The activation of COX-2 by KSHV infection [31–33,35,51], and the involvement in vGPCR
angiogenesis and tumorigenesis, as shown in this study, suggest that COX-2 could be a thera-
peutic target in KS. Primary to the definition of COX-2 as a KSHV-related therapeutic target is
Fig 6. vGPCR-transformed cells tumorigenicity is inhibited by Celecoxib treatment. A) Mice (n = 7) were injected S.C. with vGPCR-NIH3T3 cells
and treated with the COX-2 inhibitor Celecoxib I.P. or vehicle (DMSO) three times/week. On the left side, images of mice treated (lower) or not
(upper) with Celecoxib at day 15 of treatment. Tumor from non-treated (upper) or treated with Celecoxib (lower) mice are shown in detail on the right.
B) The plot shows the growth of tumor volume during the time of treatment (mean +/-range). Higher deviation in the last day for untreated animals
reflect the presence of animals with very large tumors by that day observed in all the experiments. Mice were treated with Celecoxib (black circles) or
vehicle (white circles). Tumor size was significantly lower in Celecoxib treated samples at all points of the time course (�P<0.05). C) Histological
examination of the tumors. Sections of tumors coming from mice, treated with Celecoxib or not (DMSO) as a control, were stained with Hematoxylin-
Eosin. Pictures were taken at 20x or 40x magnification. Black arrows in left panels indicates large areas of hemorrhage and necrosis.
https://doi.org/10.1371/journal.ppat.1009006.g006
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determining whether it is expressed in the majority of the KSHV infected spindle cells
(LANA-positive) of KS lesions. To evaluate this possibility, we employed double-label immu-
nohistochemistry for COX-2 and the KSHV latent nuclear antigen LANA in KS lesions. The
PEL line BC-3 was used as a positive control for KSHV infected cells. We found that in all the
KS lesions analyzed (5 out of 5) cytoplasmic staining of COX-2 (brown) was stronger in the
spindle cells expressing LANA (red) than in either spindle cells that were LANA-negative or
surrounding tissue (Fig 8, representative sample). These results indicate an association
between COX-2 over-expression and KSHV infection in spindle cells of the human KS lesions.
Discussion
Pathogenesis-based target identification has dramatically changed the way new therapies are
developed. In the case of KS, the discovery of KSHV and identification of vGPCR as a major
angiogenic oncogene provided a molecular signaling-cascade target for KSHV and Kaposi’s
sarcoma. Using this insight, we have identified molecular signaling components of the cas-
cades that are triggered by expression of the virus-encoded oncogene vGPCR and mediate its
tumorigenic capabilities [17,18,26]. Results presented hereby support the idea of COX-2 as a
Fig 7. Celecoxib treatment inhibits vGPCR tumor angiogenesis and VEGF production in the tumor and transformed cells. A) Left panels:
Immunoperoxidase staining for CD31/PECAM or SMA was performed on tumor sections. CD31/PECAM and SMA staining images of Celecoxib
treated or untreated animals are shown. Right panel: Data of staining intensity levels is represented on box-plots showing the results for the
morphometric quantification of CD31/PECAM (left) (�P<0.001) and αSMA (right) (�P<0.01) staining (n = 7). B) Tumor samples for mice tested for
tumorigenesis were homogenized and centrifuged. VEGF production was measured in the supernatants by ELISA in Celecoxib treated mice or DMSO
controls. The plot shows the mean of each group and the value of individual determinations (black circles) (�P<0.001) (n = 7). C) vGPCR-transformed
NIH3T3 cells were cultured for the indicated time and treated (grey bars) or not (black bars) with NS398 (10uM). VEGF production was measured in
the supernatants by ELISA. (�P<0.05).
https://doi.org/10.1371/journal.ppat.1009006.g007
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mediator of vGCPR triggered cell-transformation and neovascularization that might constitute
a suitable surrogate target for vGPCR angiogenesis and KSHV tumorigenesis.
The rationale for defining COX-2 as an emerging therapeutic and chemoprevention target
for various cancers [52–54] includes experimental evidence for a role in carcinogenesis or
angiogenesis using animal or cell models, together with evidence on the overexpression of
COX-2 in tumor malignant cells [27,28,54]. Here we demonstrate that vGPCR induces COX-2
transcription and mRNA stabilization with the concomitant increase in COX-2 activity via
ERK1/2 signaling pathway, and we show that COX-2 activity is critical for vGPCR pathogenic-
ity in vivo. Moreover, we were interested in the role of COX-2 in vGPCR angiogenicity
and oncogenicity as this inflammatory mediator can be targeted by low-toxicity NSAIDs in
KSHV infected cells [31,35,37,38], which makes it an interesting surrogate target for
Fig 8. COX-2 is expressed in KSHV infected spindle cells of Kaposi’s sarcoma lesions. Sections from KS biopsies
(two top panels, same patient at different magnification) or PEL (bottom panels) were incubated with COX-2 and
KSHV LANA antibodies (left panels) or Isotype control (right panels). COX-2 (cytoplasmic) bound antibodies were
developed with DAB (BROWN colored). KSHV LANA (nuclear) bound antibodies were developed with BP Red
substrate (RED colored).
https://doi.org/10.1371/journal.ppat.1009006.g008
PLOS PATHOGENS KSHV vGPCR activates COX-2 in Kaposi’s sarcoma
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009006 October 15, 2020 14 / 25
chemoprevention of KS. We used the NSAID NS398 for our in vitro experiments because this
is a very specific drug for COX-2. In contrast, we used the NSAID Celecoxib in our xenograft
model because this is an FDA-approved drug that can be potentially repurposed for its use in
clinical treatment of AIDS-KS.
We found that inhibition of COX-2 in cells with the NSAID NS398 impairs vGPCR-driven
angiogenesis, in this intradermal angiogenic assay the cells are treated with the inhibitors and
not the animals. Thus, this system is useful to evaluate the effects of the inhibitors in the angio-
genic potential of the transformed cells by vGPCR without inhibiting the host cells (including
endothelial cells). Moreover, this model mimics the physiologic conditions in which vGPCR
would turn on an angiogenic response in the dermis, where KSHV-infected spindle cells are
found. Treatment with the NSAID COX-2-selective inhibitory drug Celecoxib produced a sig-
nificant decrease in tumor growth. Tumors from animals treated with Celecoxib showed a sig-
nificant decrease in total and mature vasculature that correlated with a decrease in tumor cell
VEGF production. We therefore conclude that vGPCR regulates angiogenicity and tumorige-
nicity via COX-2 activation. Consistent with a role in KS pathogenesis and with previous
works showing COX-2 expression in KS lesions [31,55], we found that COX-2 is overexpressed
in KSHV-infected (LANA-positive) spindle cells of human KS lesions. These facts point out
COX-2 as a critical molecular component of the vGPCR transformation and angiogenic switch
and as a potential target for KS chemoprevention and therapy.
In the context of vGPCR-transformed cells and full KSHV-genome bearing cells, we
showed that a mitogenic pathway triggered by the vGPCR oncogene activates expression of
COX-2 both at the gene promoter level and by increasing mRNA stability, with the involve-
ment of MAPK signaling component (ERK1/2) in both cases. The regulation of gene expres-
sion by pathways acting both at the gene promoter level and by mRNA stabilization is an
emerging concept that we have already observed studying c-Fos gene expression regulation
[56]. Interestingly, KSHV proteins were shown to induce mRNA stability of host genes [57],
including vGPCR-induced stabilization of COX-2 mRNA in non-transformed endothelial
cells via p38/MK2 [40]. We showed that in the context of vGPCR-induced transformation and
transformed full KSHV genome bearing cells, COX-2 transcription and mRNA stability are
regulated mostly through vGPCR-triggered ERK1/2 signaling pathways. Transcription factors
are the targets of MAPK signaling that activated in turn and induce gene promoter activation.
Similarly, proteins named collectively as AUBPs bind to 3-UTR ARE regions of mRNAs, are
MAPK targets and constitute regulatory determinants in the context of the control of mRNA
stability. Identification of both the specific transcription factors and AUBPs involved in the
regulation of COX-2 expression by vGPCR is the focus of further explorations.
Our results show that COX-2 plays a key role in vGPCR angiogenesis in a murine-skin
assay and vGPCR induced tumors, indicating that COX-2 could be a link between vGPCR
receptor signaling and angiogenesis regulation. COX-2 regulates angiogenesis in endothelial
cells and inflammatory cells [58,59]. We provide evidence supporting that COX-2 inhibitors
target COX-2-mediated vGPCR angiogenicity. As shown in Fig 5 pre-treatment with the
COX-2 inhibitor NS398 repressed angiogenesis in vivo of vGPCR-transformed cells, indicating
a direct role of COX-2 in the angiogenicity of the vGPCR-expressing cells. The contribution of
COX-2 mediated angiogenesis to vGPCR tumorigenicity and angiogenicity is indicated by the
impairment of tumor growth in Celecoxib treated animals that show significant decrease in
tumor neo-vessel formation and maturation, correlated with intratumoral VEGF levels. Even
though it is possible that Celecoxib could inhibit COX-2 involvement by inhibition of targets
other than COX-2, we found that COX-2 inhibition impairs VEGF secretion in vGPCR-trans-
formed cells (Fig 7) and we also demonstrated the decrease in tumoral VEGF in animals
treated by Celecoxib. Taken together, our results provide evidence that supports that Celecoxib
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is targeting a COX-2 mediated pathway of VEGF production in vGPCR expressing tumor cells
leading to angiogenesis inhibition.
Our data suggest that COX-2 could play a role in KSHV pathobiology and KS progression
and is consistent with findings showing that COX-2 may play a role in MHV-68 replication
[51] and is induced by de novo KSHV infection [31–33,35]. We found that COX-2 is expressed
in the majority of latently-infected (LANA-positive) spindle cells of human KS lesions, as
determined by the consistency of COX-2 cytoplasmic staining in spindle-cells displaying
nuclear LANA staining (Fig 8). As generally only a small proportion of KS-spindle cells express
the early lytic gene vGPCR; it follows that COX-2 should also be upregulated in latently
infected vGPCR-negative cells, as shown in latently infected PEL cells where there is no
vGPCR expression [38]. Within these vGPCR-negative cells, COX-2 upregulation could be
caused by KSHV latent genes able to upregulate COX-2 such as LANA, vFLIP and K15
[35,42], by KSHV-dependent Nrf2 upregulation [60], or by paracrine induction of COX-2
growth factors as occurs in similar models where vGPCR expressing cells lead to secreted
mediators such as PGE2 [61], VEGF [17] or PDGF [26]. These paracrine mechanisms could
be prominent during the initial phases of KSHV tumorigenesis acting in a paracrine manner
from either lytically or abortive-lytically KSHV infected cells [62], observed in mECK36
tumors [63] and reported for a portion of KS lesions [64]. Regardless of the precise mechanism
of COX-2 expression in latently and lytically infected cells in KS lesions, our results confirm
previous findings [31,55] regarding its expression in human KS lesions. This results, together
with the expression of PGE2 receptors in KS [39], and the present identification of COX-2 acti-
vation as a key vGPCR oncogenic signaling component, further support the proposed role for
COX-2 [34,37–39] as a therapeutic target in Kaposi’s Sarcoma.
Current frontline AIDS-KS therapy includes ART, which in advanced patients or ART-
resistant individuals may additionally require systemic cytotoxic chemotherapy with liposomal
anthracyclins [3,65]. Yet, it is estimated that more than half of these patients will not be cured
[66] so new and less toxic treatment modalities are needed. Among the most promising tar-
geted therapies, Rapamycin, an mTOR inhibitor that targets the KS paracrine oncogenesis axis
and the multi-kinase inhibitor Imatinib which targets PDGFRA, c-kit and c-abl showed some
responses in transplant [67] and AIDS-KS [68] respectively. Recently, immunomodulatory
drugs as lenalidomide and pomalidomide [69] and some checkpoint inhibitors have shown
prowess in AIDS-KS treatment [3]. The identification of KSHV oncogenes, and the host-cell
signaling cascades dysregulated by them, unveil new targets and opportunities for therapeutic
intervention. Our finding that vGPCR angiogenic response is mediated by COX-2 indicates
that COX-2 could play a role in KS initiation and progression. This is supported by findings
showing that vGPCR activates COX-2 in endothelial cells [41], that KSHV de novo infection
upregulates COX-2 [31–33,35] and that KSHV-infected malignant cells of human KS lesions
express COX-2. Our results showing that COX-2 inhibition block angiogenesis and tumori-
genesis induced by the KSHV oncogene vGPCR, constitute a proof of principle for the impact
of COX-2 inhibition in KSHV pathogenicity. All these results, together with the expression of
COX-2 in KS lesions, contribute to defining COX-2 as a potential target by low-toxicity
NSAIDs for the prevention and treatment of KSHV-oncogenesis in HIV infected populations.
Materials and methods
Ethics statement
All animal experiments were conducted following the NIH guide for the Care and Use of Lab-
oratory Animals. The animal experiments have been performed under UM IACUC approval
number 16–093. The University of Miami has an Animal Welfare Assurance on file with the
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Office of Laboratory Animal Welfare (OLAW), National Institutes of Health. Additionally,
UM is registered with USDA APHIS. The Council on Accreditation of the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC International) has con-
tinued the University of Miami’s full accreditation.
Cells animals, transfections and chemicals
NIH3T3 and NIH3T3-vGPCR cells were cultured in DMEM + 10% CALF serum. SVEC and
SVEC-vGPCR cells were cultured in DMEM + 10% FBS. Transfected cells were maintained in
media containing G418 (Sigma, San Louis, Missouri). mECK36 cells were obtained and cul-
tured as described previously [63]. Tetracycline-inducible vGPCR (TET-vGPCR) mECK36
cells were obtained and cultured as previously described [26]. KSHV vGPCR-deleted mutant
and its revertant in the Bac16 platform were kindly provided by Drs. Pinghui Feng and J. Jung
(Bac16Δ-vGPCR and Bac16Δ-vGPCR-REV). We took advantage of the procedure described in
Ashlock et al.[47] whereby we swapped Bac36 for Bac16Δ-vGPCR and Bac16Δ-vGPCR-REV.
To this end we used KSHV-negative cells (mEC) from frozen populations of KSHV null
mECK36 previously obtained after 4 weeks of culturing mECK36 cells without Hygromycin
and further selected by weeding and cell sorting and characterized thoroughly for KSHV nega-
tivity by PCR for LANA, K1, vIRF-1, ORF23, ORF 36, ORF 74, and K15 [63,70].Cells were
transfected using Lipofectamine 3000 Reagent (Thermo, Waltham, Massachusetts) following
the manufacturer’s instructions. NS398 (10 μM), PD98059 (20 μM) and SB220025 (10 uM)
and SB203580 (10uM) were from Calbiochem (San Diego, California) and Celecoxib (Cele-
brex¨) was from Pharmacia, Pfizer Inc (New York, New York). Recombinant Human Gro-α/
MGSA (25nM) was from Peprotech (Rocky Hill, New Jersey).
DNA constructs
The plasmid pCOX-2-Luc was provided by Giancarlo V. De Ferrari (Centro de Tecnologı́a e
Innovación para el Cáncer (CTI-Cáncer), Department of Biochemistry and Molecular Biology,
Faculty of Biological Sciences, Universidad de Concepción, Concepción, Chile) and contains a
1.2 kb murine COX-2 promoter upstream of a luciferase gene as described previously [45].
The plasmid Luc-3’UTR-COX-2 was provided by Dan A. Dixon (Department of Oncological
Sciences, Eccles Program in Human Molecular Biology and Genetics, and the Huntsman Can-
cer Institute, University of Utah, Salt Lake City, Utah) and contains the COX-2 3’UTR region
downstream of a luciferase gene as described previously [71]. The plasmid pCEFL-AU5-
vGPCR, have been described previously [72] and was a kind gift from J.S. Gutkind laboratory.
The expression vectors for the MEKs were previously described [73].
Luciferase reporter assays
Cells were transfected with different expression plasmids together with 1ug of the indicated
reporter plasmid per well in 6-well plates. In all cases, the total amount of plasmid DNA was
adjusted with pcDNA3 empty and 0.2ug of pCDNA3-β-galactosidase. Firefly luciferase activity
present in cellular lysates was tested using the dual-luciferase reporter system (Promega,
Madison, Wisconsin.), and light emission was quantified using a luminometer (Junior
Berlthold).
COX-2 activity assay
Cells were starved overnight (O.N.) in DMEM medium with the addition of the different
inhibitors. Cell supernatants were centrifuged at 2,000 x g RT for 5 min. PGE2 levels were
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measured in those supernatants using the Prostaglandin E2 Express ELISA Kit (Cayman, Ann
Arbor, Michigan) following manufacturer’s instructions.
Western blotting
Protein concentrations in cell lysates were quantified using the DC Protein Assay (Bio-Rad).
20 μg of proteins were mixed with Laemmli buffer, boiled for 5 min, resolved by SDS-PAGE
and transferred to PVDF membranes (Bio-Rad Laboratories). Membranes were blocked with
3% BSA for 1 hour and incubated with anti-mouse COX-2 polyclonal antibody (Cayman, Ann
Arbor, Michigan), anti-mouse β-actin monoclonal antibody (Sigma, Saint Louis, Missouri),
anti-mouse GAPDH monoclonal antibody (Santa Cruz Biotechnology, Inc, Dallas, Texas),
anti-mouse ERK1/2 monoclonal antibody (Santa Cruz Biotechnology, Inc, Dallas, Texas) and
anti-mouse phospho ERK1/2 monoclonal antibody (Cell Signaling, Danvers, Massachusetts)
at 4˚C for 16 hours. After 3 TBS/T washes, membranes were incubated with HRP-labeled sec-
ondary antibodies (Promega, Madison, Wisconsin) or IRDye Secondary Antibodies (Li-COR,
Inc, Lincoln, Nebraska) for 1 hour at room temperature. Protein bands were developed using
ECL Plus Detection Reagents (GE Healthcare) or Azure Biosystems C600 Imager.
Image analysis and quantification
Band intensities corresponding to Western blot detection of protein samples were quantified
using the ImageJ software.
Real-Time quantitative PCR (RT-qPCR)
RNA was isolated with RNeasy Plus Kit (QIAGEN, Valencia, CA). RNA (500 ng) was tran-
scribed into cDNA using Reverse Transcription System (Promega, Madison, Wisconsin)
according to the manufacturer’s instructions. RT-qPCR was performed using an ABI Prism
7000 Sequence Detection System (Applied Biosystems) with SybrGreen PCR Master Mix
(Quanta Biosciences) using the primers for murine COX-2: 5’-GTGATCGAAGAC-
TACGTGCA-3’ and 5’-TCAGAGGCAATGCGGTTCTG-3, for murine GAPDH: 5’-CAATG
ACCCCTTCATTGACC-3’ and 5’-GATCTCGCTCCTGGAAGATG-3’, for Firefly luciferase:
5’-CCGCCGTTGTTGTTTTGG-3’ and 5’-ACACAACTCCTCCGCGC-3’, for Renilla Lucifer-
ase: 5’-GGAATTATAATGCTTATCTACGTGC-3’ and 5’-CTTGCGAAAAATGAAGACCT
TTTAC-3’ and for β galactosidase: 5’-CCACGGAGAATCCGACG-3’ and 5’-GCGAGGCGGT
TTTCTCC-3’. In every run, melting curve analysis was performed to verify the specificity of
products as well as water and–RT controls. Data were analyzed using the ΔΔCT method as pre-
viously described [63]. Target gene expression was normalized to GAPDH by taking the differ-
ence between CT values for target genes and GAPDH (ΔCT value). These values were then
calibrated to the control sample to give the ΔΔCT value. The fold target gene expression is
given by the formula: 2–ΔΔCT.
Angiogenesis assay
3x105 cells (two inoculation sites per mouse), treated or not with NS398 for 1hour before inoc-
ulation, were inoculated intradermally (I.D.) in Balb/C nude mice. Trypan blue (20%) was
used to assess cell viability and mark the inoculation site. Mice (5 per group) were sacrificed 5
days later. The area of inoculation was photographed under a dissecting microscope. To assess
microvessel density the whole surface area of each section was examined for morphometric
analysis following Auerbach’s criteria [74, 75]. To this extent, each photograph slide was pro-
jected in a grid corresponding to 1 square mm and the total number of blood microvessels on
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all grids having vessels was counted. The blood density was defined as the number of vessels
per grid (D = total number of vessels / total number of grids counted)[48, 76, 77].
Tumor growth assay
Mice were inoculated intra-peritoneally (I.P) with Celecoxib 10 mg/kg or vehicle (DMSO).
Later the same day they were inoculated subcutaneously (S.C.) with vGPCR transformed
NIH3T3 cells (3x105 per mouse). The animals were treated three times a week with Celecoxib
(5 mg/kg) or DMSO I.P.[49]. Tumor growth was followed by caliber measurements of volume
until the date of sacrifice.
VEGF production test
Tumor samples were weighted and homogenized in buffer TBS 0.1% BSA with the addition of
a protease inhibitor cocktail (Sigma, Saint Louis, Missouri) in a volume proportional to their
weight. Cell supernatants were assayed after centrifugation at 2,000 x g RT for 5 min. ELISA
with anti-mouse-VEGF (R&D Systems, Minneapolis, Minnesota) was performed following the
manufacturer’s instructions. VEGF levels from tumor samples were normalized based on
lysate protein concentration.
Immunohistochemistry of angiogenic markers
Frozen sections of the tumors were fixed in acetone and an immunoperoxidase staining was
performed by standard immunohistochemistry methods. Briefly: after blocking, samples were
incubated ON with anti-CD31 (Pharmingen, San Diego, CA), anti-α-SMA (Sigma, San Louis,
Missouri) or isotype-matched control antibodies as indicated. After 30 min of incubation with
goat anti rat-IgG (Pharmingen, San Diego, CA) or anti mouse-IgG kit (Vector, Burlingame,
California), for CD-31 or α-SMA respectively. Sections were developed using Elite-Vectastain
ABC-peroxidase (Vector, Burlingame, CA) for 30 min and DAB substrate (Vector, Burlin-
game, CA). Slides were counterstained with hematoxylin and mounted. Pictures were taken
using an Olympus microscope equipped with a digital camera.
Immunofluorescence staining
Immunofluorescence assay (IFA) was performed as previously described [63]. Briefly, cells
were fixed in 4% paraformaldehyde for 10 min and washed with PBS. Cells were permeabilized
in 0.2% Triton-X/PBS for 20 min at 4˚C. After blocking with 3% of BSA in PBS and 0.1%
Tween 20 for 60 min, samples were incubated with primary antibodies overnight at 4C. After
PBS washing, samples were incubated with fluorescent secondary antibodies for 1 hour
(Molecular Probes), washed and mounted with ProLong Gold antifade reagent with DAPI
(Molecular Probes). Images were taken using a Zeiss ApoTome Axiovert 200M microscope.
COX-2 and KSHV LANA double Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed paraffin-embedded biopsy
specimens of human KS lesions (1 skin, 3 lymph nodes, and 1 lung) from the tissue repository
of the Department of Pathology and Laboratory Medicine at the New York Presbiterian Hospi-
tal-Weill Cornell Medical Center. Immunohistochemical staining was performed on a Tech-
Mate 500 automated immunostainer (Ventana Medical Systems, Tucson AZ). For the COX-2
staining, sections were treated in a DAKO Antigen Retrieval Solution (DakoCytomation, Car-
pinteria, CA) and COX-2 was detected using an anti-human COX-2 antibody (Zymed Labora-
tories, San Francisco, CA) followed by an HRP-labelled secondary antibody detection system
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and DAB chromogen (DakoCytomation). For the second round of analysis by IHC, KS tissue
sections were again retrieved with a DAKO Antigen Retrieval Solution (DakoCytomation) and
KSHV-LANA was detected using a rat monoclonal to LANA-1 ORF 73 (Advanced Biotech-
nologies, MD), a secondary anti-rat biotinylated antibody (BD Pharmingen) and developed
using an ABC Alkaline-Phosphatase complex (Ventana) and BT Red Reagent substrate (Ven-
tana). Slides were counterstained with hematoxylin and mounted. Pictures were taken using
an Olympus microscope equipped with a camera.
Statistical analysis
Statistical significance of the data was determined using a two-tailed Student’s t-test and 2way
ANOVA for multiple comparisons. A p-value lower than 0.05 was considered significant. Sta-
tistical analysis was performed using GraphPad Prism 7. All the experiments were repeated at
least three times for consistency. All values were expressed as means ± standard deviation.
Supporting information
S1 Fig. Fold-changes in mRNA expression determined by RT-qPCR in mECK16 derived
cells (Δ-vGPCR or revertant virus). LANA (A) or vFLIP (B) mRNA expression levels were
measured in triplicate and are presented as means ± SD. (�P<0.05).
(TIF)
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